Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pfister

Showing results (291-300 of 754) with videos related to

Pageof 76
Sort By:
Acta Neuropathologica|August 22, 2014
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytomaFelix Sahm, David Reuss, Christian Koelsche, et al.
Journal of Neuro-Oncology|October 12, 2012
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatmentTill Milde, Marco Lodrini, Larissa Savelyeva, et al.
Nature Reviews. Disease Primers|February 16, 2019
MedulloblastomaPaul A Northcott, Giles W Robinson, Christian P Kratz, et al.
Cancer Research|August 7, 2016
Nestin Mediates Hedgehog Pathway TumorigenesisPeng Li, Eric H Lee, Fang Du, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2021
FOXR2 Stabilizes MYCN Protein and Identifies Non-<i>MYCN</i>-Amplified Neuroblastoma Patients With Unfavorable OutcomeFelix Schmitt-Hoffner, Sjoerd van Rijn, Umut H Toprak, et al.
Cell Reports|May 20, 2025
Chromatin modification abnormalities by CHD7 and KMT2C loss promote medulloblastoma progressionWanchen Wang, Kohei Kumegawa, Owen S Chapman, et al.
Neuro-Oncology Advances|April 27, 2022
Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastomaSonja Krausert, Sebastian Brabetz, Norman L Mack, et al.
JCO Precision Oncology|January 7, 2022
<i>NTRK</i> Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug TargetsElke Pfaff, Tiphaine Adam de Beaumais, Antonin Marchais, et al.
Neuro-Oncology|June 29, 2021
The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryDavid N Louis, Arie Perry, Pieter Wesseling, et al.
Acta Neuropathologica|April 29, 2019
Molecular progression of SHH-activated medulloblastomasAndrey Korshunov, Konstantin Okonechnikov, Felix Sahm, et al.
Pageof 76

Showing results (291-300 of 754) with videos related to

Sort By:
Pageof 76
Acta Neuropathologica|August 22, 2014
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytomaFelix Sahm, David Reuss, Christian Koelsche, et al.
Journal of Neuro-Oncology|October 12, 2012
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatmentTill Milde, Marco Lodrini, Larissa Savelyeva, et al.
Nature Reviews. Disease Primers|February 16, 2019
MedulloblastomaPaul A Northcott, Giles W Robinson, Christian P Kratz, et al.
Cancer Research|August 7, 2016
Nestin Mediates Hedgehog Pathway TumorigenesisPeng Li, Eric H Lee, Fang Du, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2021
FOXR2 Stabilizes MYCN Protein and Identifies Non-<i>MYCN</i>-Amplified Neuroblastoma Patients With Unfavorable OutcomeFelix Schmitt-Hoffner, Sjoerd van Rijn, Umut H Toprak, et al.
Cell Reports|May 20, 2025
Chromatin modification abnormalities by CHD7 and KMT2C loss promote medulloblastoma progressionWanchen Wang, Kohei Kumegawa, Owen S Chapman, et al.
Neuro-Oncology Advances|April 27, 2022
Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastomaSonja Krausert, Sebastian Brabetz, Norman L Mack, et al.
JCO Precision Oncology|January 7, 2022
<i>NTRK</i> Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug TargetsElke Pfaff, Tiphaine Adam de Beaumais, Antonin Marchais, et al.
Neuro-Oncology|June 29, 2021
The 2021 WHO Classification of Tumors of the Central Nervous System: a summaryDavid N Louis, Arie Perry, Pieter Wesseling, et al.
Acta Neuropathologica|April 29, 2019
Molecular progression of SHH-activated medulloblastomasAndrey Korshunov, Konstantin Okonechnikov, Felix Sahm, et al.
Pageof 76